Aptevo Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

APVO$1.08-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands, unaudited)

	For the Six Months Ended June 30,
	2024	2023
Operating Activities
Net loss	$(12,717)	$(5,175)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	992	1,380
Depreciation and amortization	197	328
Non-cash interest expense and other	—	10
Changes in operating assets and liabilities:
Royalty receivable	—	2,500
Prepaid expenses and other current assets	650	641
Operating lease right-of-use asset	236	205
Accounts payable, accrued compensation and other liabilities	(1,805)	205
Long-term operating lease liability	(357)	(331)
Net cash used in operating activities	(12,804)	(237)
Investing Activities
Net cash from investing activities	—	—
Financing Activities
Payments of long-term debt, including fees	—	(3,467)
Value of equity awards withheld for tax liability	(1)	(8)
Proceeds from issuance of common stock	3,970	2,083
Payments in lieu of fractional shares	(3)	—
Net cash provided by (used in) financing activities	3,966	(1,392)
Decrease in cash and cash equivalents	(8,838)	(1,629)
Cash and cash equivalents at beginning of period	16,904	22,635
Cash and cash equivalents at end of period	$8,066	$21,006

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.